GSK/IDIX—There was writing on the wall that something was not right with GSK2248761 (a/k/a/ IDX899)—see the bottommost paragraph of #msg-56447982. I’m curious to know why the FDA put this compound on clinical hold, but neither GSK nor IDIX is going to tell us, evidently.
The termination of IDX320 was fully expected, of course.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”